Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries

Burgos Blasco, Bárbara; García Feijoo, Julián; Ginés Gallego, Cristina; Perucho González, Lucía; Fernández Vigo, José Ignacio; Martínez De La Casa Fernández-Borrella, José María; Sáenz Francés, Federico; Morales Fernández, Laura; Méndez Hernández, Carmen Dora

Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries

Download

s00417-022-05939-5.pdf (646.69 KB)

Official URL

https://doi.org/10.1007/s00417-022-05939-5

Publication date

2023

Publisher

Springer

Citations

Exportar

URI

https://hdl.handle.net/20.500.14352/73237

Citation

Burgos Blasco, B., García Feijoo, J., Ginés Gallego, C. et al. «Efficacy and Safety of the PreserFlo Implant with Mitomycin C in Childhood Glaucoma after Previous Failed Glaucoma Surgeries». Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 261, n.o 5, mayo de 2023, pp. 1349-57. DOI.org (Crossref), https://doi.org/10.1007/s00417-022-05939-5.

Abstract

Purpose: This study aims to evaluate the efficacy and safety of the PreserFlo MicroShunt (Santen, Osaka, Japan) in lowering intraocular pressure (IOP) in childhood glaucoma patients with previous failed glaucoma surgeries. Methods: This is a prospective case review of consecutive PreserFlo procedures performed in childhood glaucoma patients after failed surgeries. Age, sex, diagnosis, and previous glaucoma surgeries, as well as visual acuity, IOP, and treatment in the preoperative visit and all follow-up visits were collected. Outcome measures included IOP reduction from baseline, mean IOP change from baseline at month 6, medication use at 6 months, complications, adverse events, and need for further procedures. Results: Fourteen patients were included, 8 (57%) males and 6 (43%) females; the mean age was 27.5 ± 13.5 years. Nine patients (64%) had at least two trabeculectomies, and 6 patients (43%) had at least one trabeculectomy and a glaucoma drainage implant. The mean IOP change from baseline was 11.3 ± 4.9 mmHg at 12 months. At 12 months, 12 patients (86%) presented ≥ 20% IOP lowering from baseline, and 11 patients (79%) presented ≥ 30%. The mean medication count decreased from 3.9 ± 0.7 (baseline) to 0.7 ± 1.3 (12 months). No intraoperative complications were reported. No adverse events were noted. No secondary filtration surgery was required, although bleb needling was required in one case, 1 month after the surgery. Conclusions: PreserFlo with MMC can be used successfully to treat uncontrolled IOP in childhood glaucoma cases with previous failed surgeries. Larger studies with longer follow-up are needed to further explore the role of the device in resistant childhood glaucoma cases.